Undisclosed PRAM (CDKL5-targeting)

About CAMP4 Therapeutics

CAMP4 Therapeutics is developing a new class of therapeutics that modulate gene expression by targeting the regulatory RNA network, a layer of biology upstream of proteins. The company's platform identifies druggable regRNA nodes to design oligonucleotide-based medicines that can precisely tune gene activity. With a focus on haploinsufficiency diseases, where increasing the output of a single healthy gene copy could provide therapeutic benefit, CAMP4 is building a pipeline with initial programs in CNS and metabolic disorders. The company is backed by leading life science investors and is advancing its lead programs toward clinical development.

Therapeutic Areas